Nalaganje...
Chronic lymphocytic leukemia at ASH 2017
At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory settin...
Shranjeno v:
| izdano v: | Memo |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Vienna
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006235/ https://ncbi.nlm.nih.gov/pubmed/29983825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0414-0 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|